As of Wednesday close, Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock was down -$1.01, moving down -3.50 percent to $27.87. The average number of shares traded per day over the past five days has been 915,340 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.75 fall in that time frame. In the last twenty days, the average volume was 1,552,365, while in the previous 50 days, it was 1,410,666.
Since last month, TNDM stock retreated -12.41%. Shares of the company fell to $26.75 on 08/09/23, the lowest level in the past month. A 52-week high of $59.91 was reached on 01/05/23 after having rallying from a 52-week low of $23.60. Since the beginning of this year, TNDM’s stock price has dropped by -38.00% or -$17.08, and marked a new high 3 times. However, the stock has declined by -53.48% since its 52-week high.
TNDM stock investors should be aware that Tandem Diabetes Care Inc. (TNDM) stock had its last reported insider trading activity 91 days ago on May 18. Allen Dick, the Director of the company, purchased of 10,000 shares for $29.47 on May 18. It resulted in a $294,687 investment by the insider. Howell Peyton R added 3,000 shares at an average price of $30.16 on May 17. The insider now owns 8,550 shares following the transaction. On May 12, EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought 3,015 shares at $32.77 apiece. The transaction was valued at $98,805.
Valuation Metrics
The stock’s beta is 0.88. Besides these, the trailing price-to-sales (P/S) ratio of 2.37, the price-to-book (PB) ratio of 5.49.
Financial Health
In the three months ended June 29, Tandem Diabetes Care Inc.’s quick ratio stood at 3.50, while its current ratio was 4.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.86, and the total debt-to-equity ratio was 0.86. On the profitability front, the trailing twelve-month gross margin is 51.20% percent. In the year ended June 29, EBITDA margin amounted to -5.93%, whereas operating margins totaled -29.30%. Based on annual data, TNDM earned $412.99 million in gross profit and brought in $801.22 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -13.10%. Return on equity (ROE) for the past 12 months was -58.70%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TNDM’s revenue fell -2.31% to $169.38 million during the quarter, while net income inched up to $195.74 million. While analysts expected Tandem Diabetes Care Inc. to report -$0.53 quarterly earnings, the actual figure was -$0.3 per share, beating the consensus estimate by 43.40%. During the quarter, the company generated -$32.59 million in EBITDA. The liabilities of Tandem Diabetes Care Inc. were 617.44 million at the end of its most recent quarter ended June 29, and its total debt was $420.28 million. The value of shareholders’ equity is $65.08 million.
Technical Picture
This quick technical analysis looks at Tandem Diabetes Care Inc.’s (TNDM) price momentum. With a historical volatility rate of 70.75%, the RSI 9-day stood at 36.40% on 16 August.
With respect to its five-day moving average, the current Tandem Diabetes Care Inc. price is down by -2.62% percent or -$0.75. At present, TNDM shares trade -11.78% below its 20-day simple moving average and -33.21% percent below its 100-day simple moving average. However, the stock is currently trading approximately +14.93% above its SMA50 and -48.34% below its SMA200.
Stochastic coefficient K was 17.71% and Stochastic coefficient D was 19.44%, while ATR was 2.00. Given the Stochastic reading of 11.12% for the 14-day period, the RSI (14) reading has been calculated as 41.63%. As of today, the MACD Oscillator reading stands at -0.76, while the 14-day reading stands at -2.25.
Analyst Ratings
Tandem Diabetes Care Inc. downgraded its rating on Tandem Diabetes Care Inc. (NASDAQ: TNDM) to a Neutral in a note to investors on August 04, 2023. The analysts firm previously had a Buy rating on the stock.
